Ionis Pharmaceuticals Says Ulefnersen Demonstrates Favorable Safety And Tolerability Profile

By Reuters News

- Ionis Pharmaceuticals, Inc. IONS.O:

  • IONIS ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 FUSION STUDY OF ULEFNERSEN MARKING SIGNIFICANT MILESTONE IN ADVANCING FIRST POTENTIAL DISEASE MODIFYING TREATMENT FOR FUS-ALS

  • IONIS PHARMACEUTICALS, - ULEFNERSEN DEMONSTRATES STATISTICALLY SIGNIFICANT IMPROVEMENT ON PRIMARY ENDPOINT IN FUS-ALS

  • IONIS PHARMACEUTICALS, - ULEFNERSEN DEMONSTRATES FAVORABLE SAFETY AND TOLERABILITY PROFILE

Further company coverage: IONS.O

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk